Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012347 | 0.86 | NAAA (0.52) | EPHX1ACHENAAA | |
| SCHEMBL20012348 | 0.86 | NAAA (0.52) | EPHX1ACHENAAA | |
| SCHEMBL8015597 | 0.80 | NOD1 (0.59) | EPHX2 | |
| SCHEMBL8015601 | 0.80 | NOD1 (0.59) | EPHX2 | |
| SCHEMBL14951131 | 0.80 | CAD (0.41) | NPC1SMN1; SMN2LMNA | |
| SCHEMBL22111291 | 0.80 | CAD (0.41) | NPC1SMN1; SMN2LMNA | |
| SCHEMBL23541601 | 0.79 | EPHX1 (0.53) | EPHX1ACHENAAA | |
| SCHEMBL111056 | 0.79 | EPHX1 (0.53) | EPHX1ACHENAAAHCAR2LMNA | |
| SCHEMBL112043 | 0.79 | EPHX1 (0.53) | EPHX1ACHENAAAHCAR2LMNA | |
| SCHEMBL113441 | 0.79 | EPHX1 (0.53) | EPHX1ACHENAAAHCAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562951-B2 | Generation of somatotropin; obtain denatured somatotropin mixture, incubate with detergent, regenerate and recover active somatotropin | MONSANTO TECHNOLOGY LLC | 2003-05-13 | — | — | US | disclosed |
| US-6410694-B1 | NATURATION OF A SOMATOTROPIN; OBTAIN SOMATOTROPIN, INCUBATE WITH DETERGENT, RECOVER SOMATOTROPIN AND REMOVE DETERGENT | MONSANTO TECHNOLOGY LLC | 2002-06-25 | — | — | US | disclosed |
| US-20020058792-A1 | Method for solubilization and naturation of somatotropins | MONSANTO TECHNOLOGY LLC | 2002-05-16 | — | — | US | disclosed |
| US-6034224-A | CONTACTING A SOMATOTROPIN WITH A C 10-18 ACYLGLUTAMATE DETERGENT COMPOSITION AND WATER AND ADJUSTING THE PH OF THE SOMATOTROPIN SOLUTION | MONSANTO COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0948540-A2 | METHOD FOR SOLUBILIZATION AND NATURATION OF SOMATOTROPINS | MONSANTO COMPANY (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029433-A2 | METHOD FOR SOLUBILIZATION AND NATURATION OF SOMATOTROPINS | MONSANTO COMPANY (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058792-A1 | Method for solubilization and naturation of somatotropins | NAA15, GOT1, CRH | EPHX1 3768/4885ACHE 2928/4885NAAA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.